Literature DB >> 17216205

Activation of soluble guanylate cyclase by nitric oxide in lymphocytes correlates with minimal hepatic encephalopathy in cirrhotic patients.

Carmina Montoliu1, Blanca Piedrafita, Miguel A Serra, Juan A del Olmo, Antonio Ferrandez, José M Rodrigo, Vicente Felipo.   

Abstract

Patients with liver cirrhosis with normal neurological and mental status examination may present minimal forms of hepatic encephalopathy, showing intellectual function impairment that cannot be detected through general clinical examination but can be unveiled using specific neuropsychological or neurophysiological examination. Evaluation of minimal hepatic encephalopathy (MHE) in cirrhotic patients would have prognostic value. The psychometric hepatic encephalopathy score (PHES) has been recommended as the "gold standard" in the diagnosis of MHE. Altered modulation of cyclic GMP (cGMP) levels in the brain seems to be responsible for the impairment of some types of cognitive function in liver disease. In animal models of liver disease, some of the alterations in modulation of cGMP levels in the brain are reproduced in lymphocytes. The aim of the present work was to assess whether there is a correlation between the alterations in different parameters involved in modulation of cGMP levels and the presence of MHE in patients with liver disease. We studied in 46 patients with liver cirrhosis and 26 controls the performance in the PHES battery of psychometric tests and the critical flicker frequency (CFF), the concentration of cGMP in plasma and lymphocytes, activation of guanylate cyclase by nitric oxide (NO) in lymphocytes, and several parameters likely involved in altered cGMP homeostasis in liver disease such as ammonia, NO metabolites, and atrial natriuretic peptide (ANP). Activation of guanylate cyclase by NO in lymphocytes and cGMP in plasma were higher and CFF lower in patients with MHE than in patients without MHE. Ammonia, ANP, and metabolites of NO were higher in patients than in controls but were no different in patients with or without MHE. Alteration in activation of guanylate cyclase by NO in lymphocytes correlates with PHES performance, CFF, and ammonia levels. This suggests that altered modulation of guanylate cyclase by NO in lymphocytes would reflect a parallel alteration in the brain occurring in patients with MHE that would be involved in their cognitive impairment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216205     DOI: 10.1007/s00109-006-0149-y

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  29 in total

1.  Critical flicker frequency for quantification of low-grade hepatic encephalopathy.

Authors:  Gerald Kircheis; Matthias Wettstein; Lars Timmermann; Alfons Schnitzler; Dieter Häussinger
Journal:  Hepatology       Date:  2002-02       Impact factor: 17.425

2.  Altered modulation of soluble guanylate cyclase in lymphocytes from patients with liver disease.

Authors:  Regina Corbalán; María-Dolores Miñana; Juan A Del Olmo; Miguel A Serra; José M Rodrigo; Vicente Felipo
Journal:  J Mol Med (Berl)       Date:  2001-10-27       Impact factor: 4.599

3.  Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.

Authors:  A Das; R K Dhiman; V A Saraswat; M Verma; S R Naik
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

4.  Neurons exposed to ammonia reproduce the differential alteration in nitric oxide modulation of guanylate cyclase in the cerebellum and cortex of patients with liver cirrhosis.

Authors:  Regina Rodrigo; Slaven Erceg; Vicente Felipo
Journal:  Neurobiol Dis       Date:  2005 Jun-Jul       Impact factor: 5.996

5.  Metallothioneins of monocytes and lymphocytes.

Authors:  M Kimura
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

6.  Correlation of nitric oxide and atrial natriuretic peptide changes with altered cGMP homeostasis in liver cirrhosis.

Authors:  Carmina Montoliu; Elena Kosenko; Juan A Del Olmo; Miguel A Serra; José M Rodrigo; Vicente Felipo
Journal:  Liver Int       Date:  2005-08       Impact factor: 5.828

7.  Neuropsychological aspects of portal-systemic encephalopathy.

Authors:  H Schomerus; W Hamster
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

8.  Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts.

Authors:  Slaven Erceg; Pilar Monfort; Mariluz Hernández-Viadel; Regina Rodrigo; Carmina Montoliu; Vicente Felipo
Journal:  Hepatology       Date:  2005-02       Impact factor: 17.425

9.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

10.  Subclinical hepatic encephalopathy impairs daily functioning.

Authors:  M Groeneweg; J C Quero; I De Bruijn; I J Hartmann; M L Essink-bot; W C Hop; S W Schalm
Journal:  Hepatology       Date:  1998-07       Impact factor: 17.425

View more
  15 in total

1.  Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy.

Authors:  Vicente Felipo; Amparo Urios; Encarna Montesinos; Inmaculada Molina; Maria L Garcia-Torres; Miguel Civera; Juan A Del Olmo; Joaquin Ortega; Jose Martinez-Valls; Miguel A Serra; Norberto Cassinello; Abdallah Wassel; Esperanza Jordá; Carmina Montoliu
Journal:  Metab Brain Dis       Date:  2011-11-10       Impact factor: 3.584

2.  Cyclic GMP in blood and minimal hepatic encephalopathy: fine-tuning of the diagnosis.

Authors:  Jan Albrecht
Journal:  J Mol Med (Berl)       Date:  2007-02-02       Impact factor: 4.599

3.  Dopamine in the pathogenesis of minimal hepatic encephalopathy: a new player?

Authors:  Rahul Rai; Radha K Dhiman
Journal:  Hepatol Int       Date:  2013-09-10       Impact factor: 6.047

4.  Dopamine Burden Triggers Neurodegeneration via Production and Release of TNF-α from Astrocytes in Minimal Hepatic Encephalopathy.

Authors:  Saidan Ding; Weikan Wang; Xuebao Wang; Yong Liang; Leping Liu; Yiru Ye; Jianjing Yang; Hongchang Gao; Qichuan Zhuge
Journal:  Mol Neurobiol       Date:  2015-10-03       Impact factor: 5.590

Review 5.  Mechanisms, diagnosis and management of hepatic encephalopathy.

Authors:  Ravi Prakash; Kevin D Mullen
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-08-10       Impact factor: 46.802

6.  Activation of neuronal nitric oxide synthase in cerebellum of chronic hepatic encephalopathy rats is associated with up-regulation of NADPH-producing pathway.

Authors:  Santosh Singh; Surendra K Trigun
Journal:  Cerebellum       Date:  2010-09       Impact factor: 3.847

Review 7.  Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications.

Authors:  Carmina Montoliu; Regina Rodrigo; Pilar Monfort; Marta Llansola; Omar Cauli; Jordi Boix; Nisrin Elmlili; Ana Agusti; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2010-03-02       Impact factor: 3.584

8.  Non invasive blood flow measurement in cerebellum detects minimal hepatic encephalopathy earlier than psychometric tests.

Authors:  Vicente Felipo; Amparo Urios; Carla Giménez-Garzó; Omar Cauli; Maria-Jesús Andrés-Costa; Olga González; Miguel A Serra; Javier Sánchez-González; Roberto Aliaga; Remedios Giner-Durán; Vicente Belloch; Carmina Montoliu
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

9.  Rats with minimal hepatic encephalopathy due to portacaval shunt show differential increase of translocator protein (18 kDa) binding in different brain areas, which is not affected by chronic MAP-kinase p38 inhibition.

Authors:  Ana Agusti; Jennifer L Dziedzic; Vicente Hernandez-Rabaza; Tomas R Guilarte; Vicente Felipo
Journal:  Metab Brain Dis       Date:  2013-12-04       Impact factor: 3.584

Review 10.  ICF, an immunodeficiency syndrome: DNA methyltransferase 3B involvement, chromosome anomalies, and gene dysregulation.

Authors:  Melanie Ehrlich; Cecilia Sanchez; Chunbo Shao; Rie Nishiyama; John Kehrl; Rork Kuick; Takeo Kubota; Samir M Hanash
Journal:  Autoimmunity       Date:  2008-05       Impact factor: 2.815

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.